Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.
Although replication-competent adenovirus (Ad) vectors are promising in AIDS vaccine design, their safety in immune compromised hosts is unknown. To initially address this question, enteric-coated tablets containing a replicating Ad vector were orally administered to SHIV- and SIV-infected rhesus macaques with normal, intermediate or low CD4 T cell counts and stable disease. The vector was detected within a week after tablet administration in stools of all animals but not in nasal secretions, indicating no spread of virus to the upper respiratory tract. CD4 T cell counts and viral loads remained stable in all animals and no signs of fever, weight loss, or other clinical symptoms of Ad-induced disease were observed during 10 weeks of follow-up. Oral delivery of the replicating Ad vector was safe and well tolerated by SHIV- and SIV-infected hosts. Oral enteric-coated tablets may prove safe for administering replicating Ad-vectored vaccines in areas with high HIV prevalence.
Gómez-Román
V Raúl
VR
NIH, NCI, Vaccine Branch, Bethesda, MD 20892, USA.
Grimes
George J
GJ
Potti
Gopal K
GK
Peng
Bo
B
Demberg
Thorsten
T
Gravlin
Luisa
L
Treece
James
J
Pal
Ranajit
R
Lee
Eun Mi
EM
Alvord
W Gregory
WG
Markham
Phillip D
PD
Robert-Guroff
Marjorie
M
D016915:AIDS Vaccines / Q000009:adverse effects* / Q000235:genetics / Q000378:metabolism; D000260:Adenoviruses, Human / Q000235:genetics* / Q000502:physiology*; D000284:Administration, Oral; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001831:Body Temperature; D018791:CD4 Lymphocyte Count; D005822:Genetic Vectors / Q000235:genetics / Q000502:physiology; D008253:Macaca mulatta / Q000502:physiology* / Q000821:virology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000821:virology*; D014766:Viremia; D014779:Virus Replication
D016915:AIDS Vaccines; D000914:Antibodies, Viral